Journal
BIODRUGS
Volume 30, Issue 2, Pages 49-74Publisher
ADIS INT LTD
DOI: 10.1007/s40259-016-0157-6
Keywords
-
Categories
Funding
- BMBF
- ERA-Net for Research on Rare Diseases
- Deutsche Forschungsgemeinschaft [GRK 1044]
- European Community [FP7/2009/241955]
- FAUN-Stiftung, Nuremberg
- Foundation Fighting Blindness (FFB) [TA-NMT-0611-0538-JGU]
- Tistou and Charlotte Kerstan Stiftung
Ask authors/readers for more resources
In recent years, remarkable advances in the ability to diagnose genetic disorders have been made. The identification of disease-causing genes allows the development of gene-specific therapies with the ultimate goal to develop personalized medicines for each patient according to their own specific genetic defect. In-depth genotyping of many different genes has revealed that similar to 12 % of inherited genetic disorders are caused by in-frame nonsense mutations. Nonsense (non-coding) mutations are caused by point mutations, which generate premature termination codons (PTCs) that cause premature translational termination of the mRNA, and subsequently inhibit normal full-length protein expression. Recently, a gene-based therapeutic approach for genetic diseases caused by nonsense mutations has emerged, namely the so-called translational read-through (TR) therapy. Read-through therapy is based on the discovery that small molecules, known as TR-inducing drugs (TRIDs), allow the translation machinery to suppress a nonsense codon, elongate the nascent peptide chain, and consequently result in the synthesis of full-length protein. Several TRIDs are currently under investigation and research has been performed on several genetic disorders caused by nonsense mutations over the years. These findings have raised hope for the usage of TR therapy as a gene-based pharmacogenetic therapy for nonsense mutations in various genes responsible for a variety of genetic diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available